Suppr超能文献

一种新型分子分级模型:Ki67与VEGF联合用于预测非侵袭性膀胱尿路上皮癌的肿瘤复发和进展

A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer.

作者信息

Chen Jun-Xing, Deng Nan, Chen Xu, Chen Ling-Wu, Qiu Shao-Peng, Li Xiao-Fei, Li Jia-Ping

机构信息

Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

出版信息

Asian Pac J Cancer Prev. 2012;13(5):2229-34. doi: 10.7314/apjcp.2012.13.5.2229.

Abstract

PURPOSE

To assess efficacy of Ki67 combined with VEGF as a molecular grading model to predict outcomes with non-muscle invasive bladder cancer (NMIBC).

MATERIALS

72 NMIBC patients who underwent transurethral resection (TUR) followed by routine intravesical instillations were retrospectively analyzed in this study. Univariate and multivariate analyses were performed to confirm the prognostic values of the Ki67 labeling index (LI) and VEGF scoring for tumor recurrence and progression.

RESULTS

The novel molecular grading model for NMIBC contained three molecular grades including mG1 (Ki67 LI≤25%, VEGF scoring≤8), mG2 (Ki67 LI>25%, VEGF scoring≤8; or Ki67 LI≤25%, VEGF scoring>8), and mG3 (Ki67 LI>25%, VEGF scoring>8), which can indicate favorable, intermediate and poor prognosis, respectively.

CONCLUSIONS

The described novel molecular grading model utilizing Ki67 LI and VEGF scoring is helpful to effectively and accurately predict outcomes and optimize personal therapy.

摘要

目的

评估Ki67联合血管内皮生长因子(VEGF)作为一种分子分级模型预测非肌层浸润性膀胱癌(NMIBC)预后的有效性。

材料

本研究回顾性分析了72例接受经尿道切除术(TUR)并进行常规膀胱内灌注的NMIBC患者。进行单因素和多因素分析以确认Ki67标记指数(LI)和VEGF评分对肿瘤复发和进展的预后价值。

结果

NMIBC的新型分子分级模型包含三个分子级别,即mG1(Ki67 LI≤25%,VEGF评分≤8)、mG2(Ki67 LI>25%,VEGF评分≤8;或Ki67 LI≤25%,VEGF评分>8)和mG3(Ki67 LI>25%,VEGF评分>8),分别提示预后良好、中等和较差。

结论

所描述的利用Ki67 LI和VEGF评分的新型分子分级模型有助于有效且准确地预测预后并优化个体化治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验